National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Lorlatinib (Lorviqua®) for 1L ALK positive NSCLC. HTA ID: 21071

Lorlatinib (Lorviqua®) as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

 

 

NCPE Assessment Process Complete
Rapid review commissioned 22/12/2021
Rapid review completed 13/01/2022
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that lorlatinib not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.